SenesTech Generates Strong Revenue Growth - Huge Upside Possible

Mark Hake • by Mark Hake CFA

Chartered Financial Analyst (CFA) • Nov 17, 2025 at 10:28 AM EST

SenesTech, which reduces rodent birth rates without poison, had 43% revenue growth and huge catalysts. It has $10.2 million in cash, worth 68% of the SNES stock price - enough to cover its burn until cash flow positive.

Image Source: Grok AI

SenesTech (SNES), which sells rat fertility-suppression products, reported excellent Q3 progress on Nov. 10, with revenue up +43.2% YoY and +10.4% QoQ. There are many catalysts for this company, which could make SNES stock worth buying.

For example, along with the release, SenesTech announced it is now selling its main product, Evolve, on Lowes.com (LOW). That complements its other e-commerce sales on Amazon.com (AMZN), a recent Sept. 2025 debut on Home Depot.com (HD), and other e-commerce sites, including on its own site.

As a result, SNES stock looks cheap here with a market cap of $15.0 million (undiluted) at low price per share. This is despite having $10.2 million in cash and no debt.

Read the full article for free on TalkMarkets here.

Disclosure:

I do not have a position in SNES stock at the time of the writing and publishing of this article.

This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and otherwise represent their own assessments and opinions. Authors are not compensated by the subject companies in any way. This article is also part of our IR Insights Initiative in which articles about participating companies can receive greater visibility. To learn more click here.

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.